Sandoz creates biosimilar unit to benefit from major patent cliff
Source: SeekingAlpha
2026-03-10 11:59:24 ET
More on Sandoz Group AG
- Sandoz Group AG 2025 Q4 - Results - Earnings Call Presentation
- Sandoz Group AG (SDZNY) Q4 2025 Earnings Call Transcript
- Sandoz: The Share Price May Have Run Its Course
- Sandoz Group AG Non-GAAP EPS of $3.64 beats by $0.38, revenue of $11.1B beats by $20M
- Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
Read the full article on Seeking Alpha
For further details see:
Sandoz creates biosimilar unit to benefit from major patent cliff
Novartis AG
NASDAQ: NVS
NVS Trading
0.77% G/L:
$162.46 Last:
2,088,215 Volume:
$161.35 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
February 22, 2026 03:07:00 pm
Novartis: This Big Pharma Giant Could Be a Sleep?at?Night Core Holding for Decades
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
